Hartmann J T, Albrecht C, Schmoll H J, Kuczyk M A, Kollmannsberger C, Bokemeyer C
Department of Hematology/Oncology/Immunology/Rheumatology, UKL-Medical Center II, Eberhard-Karls-University, Tübingen, Germany.
Br J Cancer. 1999 May;80(5-6):801-7. doi: 10.1038/sj.bjc.6690424.
This retrospective study evaluates the types and incidences of sexual disturbances and fertility distress in patients cured from testicular cancer and examines whether there is an effect resulting from different treatment modalities. A self-reported questionnaire was sent to 124 randomly selected patients who were treated at Hanover University Medical School between 1970 and 1993. Ninety-eight patients were included in the study, representing a response rate of 78%. All patients had been in complete remission (CR) for at least 24 months. The median age at diagnosis was 28 years (range 17-44). The median follow-up at the time of study was 12.0 years (range 2.8-25.6). Twenty patients (20%) had been treated for seminomatous and 78 patients (80%) for non-seminomatous germ cell tumours. Treatment included surveillance (7%), primary retroperitoneal lymph node dissection (RPLND) (13%), chemotherapy (CT) (33%), CT + secondary resection of residual retroperitoneal tumour mass (SRRTM) (43%) and infradiaphragmatic radiotherapy (4%). Patients receiving two treatment modalities (CT+SRRTM) reported more frequent an unfulfilled wish for children. Inability of ejaculation was clearly associated with RPLND and SRRTM. Subjective aspects of sexuality, like loss of sexual drive and reduced erectile potential, occurred only in a minority of patients after treatment. No abnormalities were observed concerning the course of pregnancies of partners. In conclusion, sexual dysfunction and infertility are common long-lasting sequelae in testicular cancer survivors affecting approximately 20% of patients. The relative risk for infertility appeared to be elevated for patients treated with the combination of CT+SRRTM. Twenty-one of 40 patients were able to fulfil their wish for children, and no congenital abnormalities were observed in these children.
这项回顾性研究评估了睾丸癌治愈患者性功能障碍和生育困扰的类型及发生率,并探讨了不同治疗方式是否会产生影响。我们向1970年至1993年间在汉诺威大学医学院接受治疗的124名随机选取的患者发送了一份自我报告问卷。98名患者纳入研究,回复率为78%。所有患者均处于完全缓解(CR)状态至少24个月。诊断时的中位年龄为28岁(范围17 - 44岁)。研究时的中位随访时间为12.0年(范围2.8 - 25.6年)。20名患者(20%)接受了精原细胞瘤治疗,78名患者(80%)接受了非精原细胞瘤生殖细胞肿瘤治疗。治疗方式包括观察等待(7%)、原发性腹膜后淋巴结清扫术(RPLND)(13%)、化疗(CT)(33%)、CT + 残余腹膜后肿瘤块的二次切除术(SRRTM)(43%)以及膈下放疗(4%)。接受两种治疗方式(CT + SRRTM)的患者报告未实现生育愿望的频率更高。射精功能障碍与RPLND和SRRTM明显相关。性功能的主观方面,如性欲减退和勃起功能降低,仅在少数治疗后的患者中出现。伴侣的妊娠过程未观察到异常。总之,性功能障碍和不育是睾丸癌幸存者常见的长期后遗症,约20%的患者受其影响。接受CT + SRRTM联合治疗的患者不育的相对风险似乎有所升高。40名患者中有21名能够实现生育愿望,这些孩子未观察到先天性异常。